GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KORU Medical Systems Inc (NAS:KRMD) » Definitions » Cash Ratio

KORU Medical Systems (KORU Medical Systems) Cash Ratio : 2.23 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is KORU Medical Systems Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. KORU Medical Systems's Cash Ratio for the quarter that ended in Mar. 2024 was 2.23.

KORU Medical Systems has a Cash Ratio of 2.23. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for KORU Medical Systems's Cash Ratio or its related term are showing as below:

KRMD' s Cash Ratio Range Over the Past 10 Years
Min: 1.74   Med: 2.99   Max: 8.02
Current: 2.23

During the past 13 years, KORU Medical Systems's highest Cash Ratio was 8.02. The lowest was 1.74. And the median was 2.99.

KRMD's Cash Ratio is ranked better than
66.08% of 855 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs KRMD: 2.23

KORU Medical Systems Cash Ratio Historical Data

The historical data trend for KORU Medical Systems's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KORU Medical Systems Cash Ratio Chart

KORU Medical Systems Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.44 7.45 5.29 2.50 2.58

KORU Medical Systems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.70 2.87 2.55 2.58 2.23

Competitive Comparison of KORU Medical Systems's Cash Ratio

For the Medical Instruments & Supplies subindustry, KORU Medical Systems's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KORU Medical Systems's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's Cash Ratio distribution charts can be found below:

* The bar in red indicates where KORU Medical Systems's Cash Ratio falls into.



KORU Medical Systems Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

KORU Medical Systems's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=11.482/4.454
=2.58

KORU Medical Systems's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=10.82/4.853
=2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KORU Medical Systems  (NAS:KRMD) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


KORU Medical Systems Cash Ratio Related Terms

Thank you for viewing the detailed overview of KORU Medical Systems's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


KORU Medical Systems (KORU Medical Systems) Business Description

Traded in Other Exchanges
N/A
Address
100 Corporate Drive, Mahwah, NJ, USA, 07430
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on home and specialty infusion solutions. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Executives
Manko Joseph M. Jr. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Kenneth E Miller officer: Chief Commercial Officer 26 MOUNTAINVIEW RD, WARREN NJ 07059
Edward Wholihan director C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Linda M Tharby officer: President and CEO BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
Lafrence Andrew D.c. officer: Chief Financial Officer C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas Edward Adams officer: Interim CFO 524 WOODLAND AVENUE, BRIELLE NJ 08730
Brian Case officer: Chief Technology Officer 424 CYPRUS CIR, LAKE VILLA IL 60046-8629
Shahriar Matin director 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Donna French director 25 SEARSVILLE COURT, HILLSBOROUGH CA 94010
Donald B Pettigrew officer: Pres./Chief Commercial Officer 7871 ENGEN LOOP, PARK CITY UT 84098
Karen Fisher officer: CFO 24 CARPENTER ROAD, CHESTER NY 10918
Daniel S Goldberger director 24 CARPENTER ROAD, CHESTER NY 10918
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Horton Freedom, L.p. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103